Encompass Health Co. (NYSE:EHC) Stock Holdings Boosted by Oppenheimer & Co. Inc.

Oppenheimer & Co. Inc. raised its position in shares of Encompass Health Co. (NYSE:EHC) by 5.6% in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 118,201 shares of the company’s stock after purchasing an additional 6,280 shares during the quarter. Oppenheimer & Co. Inc. owned about 0.12% of Encompass Health worth $9,761,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Principal Securities Inc. acquired a new stake in shares of Encompass Health during the 4th quarter valued at $25,000. Benjamin F. Edwards & Company Inc. lifted its position in shares of Encompass Health by 360.2% during the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 405 shares of the company’s stock valued at $27,000 after acquiring an additional 317 shares during the last quarter. McGlone Suttner Wealth Management Inc. acquired a new stake in shares of Encompass Health during the 4th quarter valued at $30,000. GAMMA Investing LLC purchased a new stake in shares of Encompass Health in the fourth quarter valued at $33,000. Finally, Parallel Advisors LLC lifted its holdings in shares of Encompass Health by 192.3% in the fourth quarter. Parallel Advisors LLC now owns 573 shares of the company’s stock valued at $38,000 after purchasing an additional 377 shares in the last quarter. 97.25% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research firms have recently issued reports on EHC. Barclays increased their target price on Encompass Health from $108.00 to $113.00 and gave the company an “overweight” rating in a report on Wednesday. Stephens restated an “overweight” rating and issued a $94.00 target price on shares of Encompass Health in a report on Wednesday, June 5th. SVB Leerink initiated coverage on Encompass Health in a report on Wednesday. They set an “outperform” rating and a $100.00 price objective for the company. Royal Bank of Canada increased their target price on shares of Encompass Health from $83.00 to $95.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 22nd. Finally, Raymond James reissued a “strong-buy” rating and set a $95.00 target price (up from $85.00) on shares of Encompass Health in a research report on Friday, April 26th. Nine analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $94.75.

Encompass Health Stock Performance

Shares of NYSE:EHC traded up $0.64 during midday trading on Friday, hitting $86.54. The company’s stock had a trading volume of 482,385 shares, compared to its average volume of 618,448. The stock has a market capitalization of $8.71 billion, a price-to-earnings ratio of 23.39, a PEG ratio of 1.34 and a beta of 0.89. The stock’s 50 day simple moving average is $85.30 and its 200 day simple moving average is $78.74. Encompass Health Co. has a fifty-two week low of $57.55 and a fifty-two week high of $87.94. The company has a debt-to-equity ratio of 1.14, a quick ratio of 1.37 and a current ratio of 1.37.

Encompass Health (NYSE:EHC) last issued its quarterly earnings results on Wednesday, April 24th. The company reported $1.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.93 by $0.19. Encompass Health had a return on equity of 18.01% and a net margin of 7.60%. The company had revenue of $1.32 billion for the quarter, compared to the consensus estimate of $1.27 billion. During the same period last year, the business posted $0.88 earnings per share. The firm’s revenue was up 13.4% compared to the same quarter last year. As a group, research analysts anticipate that Encompass Health Co. will post 4.09 earnings per share for the current year.

Encompass Health Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, July 15th. Investors of record on Monday, July 1st will be paid a $0.15 dividend. This represents a $0.60 annualized dividend and a dividend yield of 0.69%. The ex-dividend date is Monday, July 1st. Encompass Health’s payout ratio is presently 16.22%.

Insider Activity at Encompass Health

In related news, insider Elissa Joy Charbonneau sold 10,000 shares of the stock in a transaction dated Friday, May 24th. The shares were sold at an average price of $85.02, for a total value of $850,200.00. Following the completion of the sale, the insider now owns 18,594 shares in the company, valued at $1,580,861.88. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In other Encompass Health news, Director Greg D. Carmichael purchased 2,000 shares of the business’s stock in a transaction on Friday, May 3rd. The stock was purchased at an average price of $83.73 per share, for a total transaction of $167,460.00. Following the completion of the purchase, the director now directly owns 17,050 shares in the company, valued at $1,427,596.50. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Elissa Joy Charbonneau sold 10,000 shares of the firm’s stock in a transaction dated Friday, May 24th. The stock was sold at an average price of $85.02, for a total transaction of $850,200.00. Following the transaction, the insider now owns 18,594 shares of the company’s stock, valued at approximately $1,580,861.88. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 69,519 shares of company stock worth $5,816,091. Company insiders own 2.10% of the company’s stock.

Encompass Health Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.